Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asenapine vs olanzapine for predominant persistent negative symptoms of schizophrenia
2004-002560-17Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asenapine in schizophrenia (2 arms), sponsored by Organon & Co. Primary endpoint: Negative Symptom Assessment change at 6 months. Started Dec 2004; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2004-002560-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002560-17.